107793-72-6

中文名称碘昔兰

英文名称 IOXILAN (400 MG)

CAS 107793-72-6

分子式 C18H24I3N3O8

分子量 791.11

MOL 文件 107793-72-6.mol

更新日期 2024/03/22 17:31:03

107793-72-6 结构式

基本信息物理化学性质安全数据碘昔兰价格(试剂级) 常见问题列表

基本信息

中文别名

碘昔兰
碘昔兰 USP标准品

英文别名

Ioxitol
Oxilan 300
IOXILAN (400 MG)
5-[Acetyl(2,3-dihydroxypropyl)aMino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide
1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-
1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-
5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide

物理化学性质

沸点827.8±65.0 °C(Predicted)

密度2.205±0.06 g/cm3(Predicted)

储存条件-20°C储存

溶解度DMSO: ≥ 250 mg/mL (316.01 mM)

酸度系数(pKa)11.47±0.46(Predicted)

形态Solid

颜色White to off-white

主要应用pharmaceutical (small molecule)

InChI1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)

InChIKeyUUMLTINZBQPNGF-UHFFFAOYSA-N

SMILESIc1c(c(c(c(c1C(=O)NCC(O)CO)I)C(=O)NCCO)I)N(CC(O)CO)C(=O)C

EPA化学物质信息1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo- (107793-72-6)

安全数据

WGK GermanyWGK 3

海关编码2924296000

存储类别11 - Combustible Solids

碘昔兰价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2026/06/05	HY-109513	碘昔兰 Ioxilan	107793-72-6	5 mg	1100元
2026/06/05	HY-109513	碘昔兰 Ioxilan	107793-72-6	10 mg	1750元
2026/06/05	HY-109513	碘昔兰 Ioxilan	107793-72-6	10 mM * 1 mL in DMSO	1914元

常见问题列表

生物活性

Ioxilan 是一种低渗，非离子和三碘化的诊断造影剂。Ioxilan 还是 X 射线造影剂，用于排泄性尿路造影和头部和身体的造影剂增强计算机断层扫描 (CECT) 成像。血管内注射使造影剂流动路径中的血管变得不透明，从而可以对人体内部结构进行射线照相可视化，直到发生明显的血液稀释为止。

体外研究

As a low-osmolar nonionic monomer, Ioxilan increases the safety and tolerance of X-ray contrast agents. The development of Ioxilan is based on the introduction of a double methylene as a hydrophobic region and masking it with a hydrophilic hydroxyl group could lower the osmolality without adversely affecting the biological tolerance.

体内研究

Rapid intravenous injection of water-soluble X-ray contrast agents (Ioxilan) can be performed with dynamic computed tomography to improve the detectability of liver lesions. When injected intravenously, water-soluble, intravenous X-ray contrast agents are largely distributed in the extracellular fluid space and excreted unchanged by the kidneys. Contrast enhancement of a region of interest depends on the route of administration, delivery of the agent to the area by blood flow, and the final iodine concentration in the region.